Immunotherapy combo targets rare, aggressive lung cancer
NCT ID NCT06049966
First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time
Summary
This trial investigates whether adding the immunotherapy drug atezolizumab (Tecentriq) to standard chemotherapy (carboplatin and etoposide) helps people with a rare and aggressive lung cancer called large cell neuroendocrine carcinoma (LCNEC). The study enrolls adults with advanced or metastatic LCNEC who have not had prior treatment. Researchers measure how long patients live without the cancer worsening, overall survival, and tumor shrinkage. They also look at blood markers called miR-21 and miR-375 to see if they can predict treatment response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- atezolizumab (Tecentriq) plus carboplatin and etoposide
- What this could lead to
- If successful, this could offer a new treatment option for a rare and aggressive lung cancer, potentially improving survival and response rates.
- What could go wrong
- This is an early-phase, small study (22 people) with no randomization. The drug may not work better than chemo alone, and side effects from immunotherapy can be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE CARCINOMA OF THE LUNG are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National and Kapodistrian University of Athens
Athens, 11527, Greece
-
OCEBER
Athens, Athens, 11527, Greece
-
Sotiria Thoracic Diseases General Hospital of Athens
Athens, 115 27, Greece
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New drug cocktail aims to tame rare lung cancer
- Triple-Drug cocktail takes aim at rare, aggressive cancers
- Engineered immune cells take aim at tough lung cancer
- Radioactive drug targets tough lung cancers in early trial
- New hope for Chemo-Resistant lung cancers?
- Immunotherapy plus chemo shows promise for rare lung cancer